PR92230

HYDERABAD, India, October 11, 2021 /PRNewswire=KYODO JBN/ -

    - Completes two-thirds of its investment target of US$150M

    - Demonstrates a leap forward in capabilities across all focus areas –

People, Processes, and Infrastructure

    Sai Life Sciences, a leading global Contract Research, Development and

Manufacturing Organisation [https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=sai-nxt-midterm-report](CRO-CDMO),

today presented a midterm report on its organizational transformative

initiative, Sai Nxt. Envisaged as a 4-year program from 2019 to 2023 with an

investment target of US$150M, Sai Nxt [https://www.sailife.com/sai-nxt/?utm_source=pr&utm_medium=web&utm_campaign=sai-nxt-midterm-report]

has enabled a transformation in the company’s capabilities across three core

areas: (1) People & culture (2) Processes & automation (3) Infrastructure &

scientific capabilities.

    CEO & Managing Director of Sai Life Sciences, Krishna Kanumuri, said, “At

the halfway mark of Sai Nxt, we have completed two-thirds of our committed

investment. More importantly, it has augmented our ability to serve the needs

of global pharma and biotech innovators with speed, compliance and

dependability.”

    En route to excellence: Highlights from the journey so far

    Guided by the insights and feedback from its innovator customers, Sai Life

Sciences has expanded its R&D and manufacturing facilities [https://www.sailife.com/pharmaceutical-cro-cdmo-about-sai-life-sciences/facilities/?utm_source=pr&utm_medium=web&utm_campaign=sai-nxt-midterm-report],

deepened scientific & technological capabilities [https://www.sailife.com/services/?utm_source=pr&utm_medium=web&utm_campaign=sai-nxt-midterm-report],

strengthened automation and data systems, and raised the bar for safety, quality and customer focus.

    1. Growth in scientific depth and scale: The company’s expansion into

Boston and Manchester has enabled it to access some of the finest

pharmaceutical talent globally and strengthened its ability to solve complex

scientific challenges. The simultaneous growth in its India team has brought in

niche capabilities and NCE experience.

    2. Expansion in technology platforms and capabilities: The company has

augmented its capabilities across various technologies including high-content

screening (HCS), PROTACS, particle sciences & engineering, highly potent APIs,

scale-up of flow processes, amidites, peptides, and more.

    3. Fully integrated discovery and development campus, built for speed: The

company has consolidated all its India R&D capabilities into a 13-acre

integrated campus in Hyderabad with 1200+ scientists. The campus houses

integrated discovery (chemistry, biology and DMPK/ tox), early & late phase

development, comprehensive analytical capabilities, process safety, technology

platforms, early phase supplies, and technology transfer. The co-location of

cross-functional teams on the same site, combined with streamlined processes

and automation, helps faster resolution of technical issues and improves speed.

    4. Global delivery model for biology and process chemistry: To provide its

customers an optimal solution in terms of talent, speed, and cost efficiency,

the company has created specialized global R&D teams in Boston (Biology) and

Manchester (Process Development) with proven ability to solve complex

scientific challenges. Complementing the strong track record of handling

complex projects by the India team, this allows customers the choice to begin

their project in Boston or Manchester, following which projects are seamlessly

tech transferred to Hyderabad for greater throughput or scale-up, as needed.

This model is enabled by unified global teams supported by matching

infrastructure and processes across all sites.

    5. New state-of the-art manufacturing facilities: The company has added 172

KL API & intermediate manufacturing capacity, 4 Clean rooms, at its Bidar

manufacturing campus. It is on course to adding highly potent API and amidites

capabilities by end-2021, additional 200 KL manufacturing capacity and a

dedicated facility for companion animal health products by end-2022. With this

expansion, 80% of the installed capacity will be under 5 years old, and 60%

under 3 years old. All new production facilities have state-of-the-art

automation, data systems and safety features housed in ergonomically designed

multi-purpose production blocks.

    6. Global customer outreach: The company has expanded its business

development footprint [https://www.sailife.com/pharmaceutical-cro-cdmo-about-sai-life-sciences/contact/?utm_source=pr&utm_medium=web&utm_campaign=sai-nxt-midterm-report]

to 15 cities around the world with the aim of elevating its customer-service

levels and having representation closer to customers.

    7. Renewed thrust on Sustainability: Sai Life Sciences has made significant

progress in advancing its Sustainability agenda:

      - Became the first India-headquartered company to join the PSCI

membership [https://www.sailife.com/sai-life-sciences-becomes-first-india-headquartered-company-to-join-pharmaceutical-supply-chain-initiative-psci/?utm_source=pr&utm_medium=web&utm_campaign=sai-nxt-midterm-report]

      - Joined ACS Green Chemistry Institute Pharmaceutical Roundtable

(ACS-GCIPR [https://www.sailife.com/sai-life-sciences-joins-the-acs-green-chemistry-institute-pharmaceutical-roundtable/?utm_source=pr&utm_medium=web&utm_campaign=sai-nxt-midterm-report]) as an ‘Associate Member’

      - Released its first Sustainability Report

[https://www.sailife.com/sai-life-sciences-releases-its-first-sustainability-rep

ort/?utm_source=pr&utm_medium=web&utm_campaign=sai-nxt-midterm-report] in 2020

as per GRI framework

      - Received ISO 14001:2015 and ISO 45001:2018 certifications [https://www.sailife.com/sai-life-sciences-receives-iso-140012015-and-iso-450012018-certification/?utm_source=pr&utm_medium=web&utm_campaign=sai-nxt-midterm-report]

      - Became signatory of United Nations Global Compact [https://www.sailife.com/sai-life-sciences-becomes-a-signatory-of-the-united-nations-global-compact-ungc/?utm_source=pr&utm_medium=web&utm_campaign=sai-nxt-midterm-report](UNGC)

    8. Certifications, Awards & Recognition: As a testimony to its

transformation, Sai Life Sciences has won several prestigious awards and

recognition across diverse categories including quality [https://www.sailife.com/commitment/quality/?utm_source=pr&utm_medium=web&utm_campaign=sai-nxt-midterm-report],

learning & development, efficient energy practices and sustainability [https://www.sailife.com/commitment/sustainability/?utm_source=pr&utm_medium=web&utm_campaign=sai-nxt-midterm-report].

More details about Sai Nxt can be found here [https://www.sailife.com/sai-nxt/?utm_source=pr&utm_medium=web&utm_campaign=sai-nxt-midterm-report].

    About Sai Life Sciences

    Sai Life Sciences is a full-service CRO-CDMO [https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=sai-nxt-midterm-report]

that works with innovator pharma and biotech companies globally, to accelerate

the discovery, development and commercialisation of complex small molecules.

The company has over 2200 employees across its facilities in India, UK and USA.

Sai Life Sciences is privately held and backed by global investors, TPG Capital

and HBM Healthcare Investments. https://www.sailife.com/.

    Photo: https://mma.prnewswire.com/media/1656857/Sai_Nxt.jpg

    Logo: https://mma.prnewswire.com/media/1044186/Sai_Life_Sciences_Logo.jpg

    Source: Sai Life Sciences